Barclays PLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Barclays PLC acquired a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 19,616 shares of the company’s stock, valued at approximately $304,000. Barclays PLC owned 0.08% of Artiva Biotherapeutics at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $42,000. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $135,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $623,000. Acuta Capital Partners LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $680,000. Finally, State Street Corp acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $1,337,000.

Artiva Biotherapeutics Stock Up 7.0 %

Shares of ARTV stock opened at $10.67 on Monday. The business’s fifty day moving average price is $11.37. Artiva Biotherapeutics, Inc. has a 1 year low of $9.68 and a 1 year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). As a group, research analysts predict that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on ARTV. HC Wainwright began coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $21.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.